Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer

Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. To address this issue, we performed an integrativ...

Full description

Bibliographic Details
Authors: Frigola Rissech, Joan|||0000-0003-1887-2432, Navarro, Alejandro|||0000-0001-5903-270X, Carbonell, Caterina|||0000-0001-6508-1858, Callejo, Ana|||0000-0003-2556-8412, Iranzo, Patricia|||0000-0002-9335-2472, Cedrés, Susana|||0000-0002-0648-7978, Martinez-Marti, Alex|||0000-0002-6714-9526, Pardo Aranda, Nuria, Saoudi-Gonzalez, Nadia|||0000-0001-6044-1703, Martínez, Débora, Jiménez, José, Sansano, Irene|||0000-0003-0188-5210, Mancuso, Francesco M.|||0000-0001-5499-6630, Nuciforo, Paolo|||0000-0003-1380-0990, Montuenga, Luis M., Sánchez Céspedes, Montse|||0000-0002-6045-5627, Prat, Aleix|||0000-0003-2377-540X, Vivancos, Ana|||0000-0003-2888-6512, Felip, Enriqueta|||0000-0002-7620-0098, Amat, Ramon|||0000-0001-8284-2540
Format: article
Publication Date:2020
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:236714
Online Access:https://ddd.uab.cat/record/236714
https://dx.doi.org/urn:doi:10.1002/1878-0261.12891
Access Level:Open access
Keyword:NSCLC
PD-L1
Chromosomal alterations burden
Copy number alterations
Immune checkpoint inhibitors
Long-term benefit
Tumor mutational burden
Description
Summary:Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. To address this issue, we performed an integrative analysis of genomic and transcriptomic features of long-term immune checkpoint inhibitors (ICIs)-associated responders. We assembled a cohort of 47 patients with NSCLC receiving ICIs that was enriched in long-term responders [.

Similar Items